Comparative Efficacy and Safety of Topical Cyclosporine, Dexamethasone and Loteprednol in Vernal Keratoconjunctivitis
Keywords:
dexamethasone, cyclosporine, loteprednol, vernal keratoconjunctivitisAbstract
Introduction: Vernal keratoconjunctivitis is a chronic, severe, recurrent and bilateral seasonal allergic conjunctivitis causing vision threatening complications for which drugs like topical corticosteroids and cyclosporine are required for severe inflammation.
Aims &Objectives: To compare the efficacy and safety of topical cyclosporine, dexamethasone and loteprednol in vernal keratoconjunctivitis.
Place and Duration of Study: Department of Ophthalmology, Shaikh Zayed Hospital, Lahore from 1st December 2019 to 30th June 2020.
Materials & Methods: A randomized controlled trial in which one hundred and fifty patients of VKC (vernal keratoconjunctivitis) were enrolled in which 50 were from cyclosporine group, 50 were from dexamethasone group and 50 were from loteprednol group. Detailed ocular and systemic histories were recorded followed by ocular examination including recording of visual acuity, intraocular pressure (IOP) measurements, slit lamp examination of anterior segment and fundoscopy.
Results: The mean ages of the patients were 18.12±7.76 years, 17.02±7.22 years and 17.50±7.22 years in cyclosporine, dexamethasone and loteprednol groups respectively. At 1st week, in cyclosporine, dexamethasone and loteprednol groups the mean intraocular pressures of patients were 16.09±1.44 mmHg, 16.39±1.37 mmHg and 16.69±1.46 mmHg respectively (P=0.114). Similarly at 6th months follow-up in cyclosporine, dexamethasone and loteprednol groups, the mean intraocular pressure of patients was 16.09±1.44 mmHg, 17.26±1.13 mmHg and 16.67±1.44 mmHg respectively (P=0.000). Posterior subcapsular opacity of lens was observed in one case in dexamethasone group while in both other groups no posterior subcapsular opacity of lens occurred.
Conclusion: Cyclosporine is a safe and effective drug as compared to dexamethasone and loteprednol in treating vernal keratoconjunctivitis.
References
Badawi NM. Supratarsal injections versus topical steroids in resistant vernal keratoconjunctivitis. Delta Journal of Ophthalmology 2018;19(4):211.
das Neves Almeida Sandrin L, Santo RM. Ocular allergy therapy perspectives: Review on the main therapeutic targets. Revista Brasileira de Oftalmologia 2015;74(5).
Leonardi A, Bogacka E, Fauquert J, Kowalski M, Groblewska A, Jedrzejczak?Czechowicz M, et al. Ocular allergy: recognizing and diagnosing hypersensitivity disorders of the ocular surface. Allergy 2012;67(11):1327-37.
La Rosa M, Lionetti E, Reibaldi M, Russo A, Longo A, Leonardi S, et al. Allergic conjunctivitis: a comprehensive review of the literature. Italian journal of pediatrics 2013;39(1):18.
Bremond-Gignac D, Donadieu J, Leonardi A, Pouliquen P, Doan S, Chiambarretta F, et al. Prevalence of vernal keratoconjunctivitis: a rare disease? British journal of ophthalmology 2008;92(8):1097-102.
De Smedt S, Wildner G, Kestelyn P. Vernal keratoconjunctivitis: an update. British Journal of Ophthalmology 2013;97(1):9-14.
Zicari A, Nebbioso M, Lollobrigida V, Bardanzellu F, Celani C, Occasi F, et al. Vernal keratoconjunctivitis: atopy and autoimmunity. Eur Rev Med Pharmacol Sci 2013;17(10):1419-23.
Friedlaender MH. Ocular allergy. Current opinion in allergy and clinical immunology 2011;11(5):477-82.
hyung Kim T, ju Moon N. Clinical correlations of dry eye syndrome and allergic conjunctivitis in Korean children. Journal of pediatric ophthalmology and strabismus 2013;50(2):124-7.
Droitcourt C, Touboul D, Ged C, Ezzedine K, Cario-Andre M, De Verneuil H, et al. A prospective study of filaggrin null mutations in keratoconus patients with or without atopic disorders. Dermatology 2011;222(4):336-41.
Li Z, Mu G, Chen W, Gao L, Jhanji V, Wang L. Comparative evaluation of topical pranoprofen and fluorometholone in cases with chronic allergic conjunctivitis. Cornea 2013;32(5):579-82.
Feiz V, Oberg TJ, Kurz CJ, Mamalis N, Moshirfar M. Nepafenac-associated bilateral corneal melt after photorefractive keratectomy. Cornea 2009;28(8):948-50.
Brady CJ, Villanti AC, Law HA, Rahimy E, Reddy R, Sieving PC, et al. Corticosteroid implants for chronic non?infectious uveitis. Cochrane Database of Systematic Reviews 2016(2).
Diane D-S, Acheampong A. Ocular pharmacokinetics and safety of ciclosporin, a novel topical treatment for dry eye. Clinical pharmacokinetics 2005;44(3):247-61.
Wan Q, Tang J, Han Y, Wang D, Ye H. Therapeutic effect of 0.1% tacrolimus eye drops
in the tarsal form of vernal keratoconjunctivitis. Ophthalmic research 2018;59(3):126-34.
Levy O, Labbe A, Borderie V, Laroche L, Bouheraoua N. Topical cyclosporine in ophthalmology: Pharmacology and clinical indications. Journal francais d'ophtalmologie 2016;39(3):292-307.
Lee JH, Min K, Kim SK, Kim EK, Kim T-i. Inflammatory cytokine and osmolarity changes in the tears of dry eye patients treated with topical 1% methylprednisolone. Yonsei medical journal 2014;55(1):203-8.
Abadia B, Calvo P, Ferreras A, Bartol F, Verdes G, Pablo L. Clinical Applications of Dexamethasone for Aged Eyes. Drugs & aging 2016;33(9):639-46.
Kumar S. Vernal keratoconjunctivitis: a major review. Acta ophthalmologica 2009;87(2):133-47.
Bonini S, Bonini S, Lambiase A, Marchi S, Pasqualetti P, Zuccaro O, et al. Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term followup. Ophthalmology 2000;107(6):1157-63.
Vichyanond P, Pacharn P, Pleyer U, Leonardi A. Vernal keratoconjunctivitis: a severe allergic eye disease with remodelling changes. Pediatric allergy and immunology 2014;25(4):314-22.
Sutyawan WE, Widiastuti IAP, Ryalino C. Steroid Induced Cataract in Langerhans Cell Histiocytosis Patient. Open Access Maced J Med Sci 2019;7(6):1025-8.
Mehta JS, Chen WL, Cheng ACK, Cung LX, Dualan IJ, Kekunnaya R, Khaliddin N, Kim TI, Lam DK, Leo SW, Manurung F, Tesavibul N, Bremond-Gignac D. Diagnosis, Management, and Treatment of Vernal Keratoconjunctivitis in Asia: Recommendations From the Management of Vernal Keratoconjunctivitis in Asia Expert Working Group. Front Med (Lausanne). 2022 Aug 1;9:882240.
Bonini S, Coassin M, Aronni S, Lambiase A. Vernal keratoconjunctivitis. Eye (Lond) 2004 Apr;18(4):345-51.
Brindisi G, Cinicola B, Anania C, De Castro G, Nebbioso M, Miraglia Del Giudice M, Licari A, Caffarelli C, De Filippo M, Cardinale F, Duse M, Zicari AM. Vernal keratoconjunctivitis: state of art and update on treatment. Acta Biomed. 2021 Nov 29;92(S7):e2021517.
Singhal D, Sahay P, Maharana PK, Raj N, Sharma N, Titiyal JS. Vernal Keratoconjunctivitis. Surv Ophthalmol. 2019 May-Jun;64(3):289-311.
Schmid KL, Schmid LM. Ocular allergy: causes and therapeutic options. Clinical and Experimental Optometry 2000;83(5):257-70.
De Smedt S, Nkurikiye J, Fonteyne Y, Tuft S, De Bacquer D, Gilbert C, et al. Topical ciclosporin in the treatment of vernal keratoconjunctivitis in Rwanda, Central Africa: a prospective, randomised, double-masked, controlled clinical trial. British journal of ophthalmology 2012;96(3):323-8.
Willen CM, McGwin G, Liu B, Owsley C, Rosenstiel C. Efficacy of cyclosporine 0.05% ophthalmic emulsion in contact lens wearers with dry eyes. Eye & Contact Lens 2008;34(1):43-5.
Secchi AG, Tognon MS, Leonardi A. Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis. American journal of ophthalmology 1990;110(6):641-5.
Pucci N, Novembre E, Cianferoni A, Lombardi E, Bernardini R, Caputo R, et al. Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Annals of Allergy, Asthma & Immunology 2002;89(3):298-303.
Neri Pucci, Elio Massimo Novembre, Antonella Cianferoni, Enrico Lombardi. Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Annals of allergy, asthma & immunology 2002.
Chatterjee A, Bandyopadhyay S, Bandyopadhyay SK. Efficacy, Safety and Steroid-sparing Effect of Topical Cyclosporine A 0.05% for Vernal Keratoconjunctivitis in Indian Children. Journal of ophthalmic & vision research 2019;14(4):412.
Yücel OE, Ulus ND. Efficacy and safety of topical cyclosporine A 0.05% in vernal keratoconjunctivitis. Singapore medical journal 2016;57(9):507.
Schultz C. Safety and efficacy of cyclosporine in the treatment of chronic dry eye. Ophthalmol Eye Dis 2014;6:37-42.
Baiza-Duran L, González-Villegas A, Contreras-Rubio Y, Juarez-Echenique J, Vizzuett-Lopez I, Suarez-Sanchez R. Safety and efficacy of topical 0.1% and 0.05% cyclosporine A in an aqueous solution in steroid-dependent vernal keratoconjunctivitis in a population of Mexican children. J Clin Exp Ophthalmol 2010;1:115.
Çoban-Karata? M, Özkale Y, Altan-Yayc?o?lu R, S?zmaz S, Pelit A, Metindo?an S, et al. Efficacy of topical 0.05% cyclosporine treatment in children with severe vernal keratoconjunctivitis. Turkish Journal of Pediatrics 2014;56(4).
Ozcan AA, Ersoz TR, Dulger E. Management of severe allergic conjunctivitis with topical cyclosporin a 0.05% eyedrops. Cornea 2007;26(9):1035-8.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Proceedings
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a 